Last updated: April 18, 2026
Who are the manufacturing and distribution partners for DAYVIGO?
DAYVIGO (lasmemtenan) is a prescription medication developed by Eli Lilly and Company. It is used for treating insomnia characterized by difficulty with sleep onset and/or sleep maintenance.
Manufacturing and Supply Chain Overview
Eli Lilly manufactures DAYVIGO internally, supported by a network of global contract manufacturing organizations (CMOs) for active pharmaceutical ingredient (API) production and formulation. Key supplier categories include:
- API Suppliers
- Formulation and Finished Product Manufacturers
- Packaging and Labeling Vendors
- Logistics and Distribution Partners
Active Pharmaceutical Ingredient (API) Suppliers
Lasmemtenan, the API for DAYVIGO, is produced predominantly by Eli Lilly’s own API manufacturing facilities. The company maintains tight control over API quality and supply chain security.
Known API manufacturing locations:
- Indian Facilities: Eli Lilly operates API plants in Chennai and Paonta Sahib.
- U.S. Facilities: API production in Lilly’s U.S. plants, ensuring regional supply reliability.
Third-party API sources: No public disclosures indicate reliance on external API suppliers for lasmemtenan. Eli Lilly prefers in-house manufacturing for quality control and intellectual property reasons.
Formulation and Finished Product Manufacturers
Eli Lilly outsources some of its formulation, filling, and finish operations to Contract Manufacturing Organizations. These often include:
- Catalent: Known for packaging, packaging, and final drug product manufacturing for Lilly.
- Lonza: Potential provider for specialized formulation or fill-finish services.
The specific partners vary by country and manufacturing scale, with Lilly maintaining oversight on regulatory compliance and quality.
Packaging and Labeling Service Providers
Dayvigo’s packaging is managed by specialized vendors, often including:
- Siegfried AG: For secondary packaging in some regions.
- Local packaging partners: Vary by country, complying with regional regulatory authorities.
Logistics and Distribution
Lilly controls distribution through its global logistics network, involving third-party freight providers specializing in cold chain and temperature-sensitive pharmaceuticals:
- DHL Supply Chain
- UPS Healthcare
Distribution is managed through regional warehouses to ensure timely delivery to pharmacies and hospitals worldwide.
Regulatory Approvals and Supply Status
Eli Lilly received FDA approval for DAYVIGO in August 2019. The company has scaled manufacturing to meet global demand, with regional manufacturing enhancements in Europe and Asia.
Supply Chain Risks and Dependencies
- API production concentration: Dependence on Lilly’s own facilities limits external risk but introduces capacity constraints.
- Third-party partners: Bottlenecks at CMOs can affect supply continuity.
- Logistical disruptions: Global events such as pandemics or supply chain disruptions impact distribution.
Competitive Supplier Landscape
Current supplier setup is largely controlled by Eli Lilly, with limited external competition for LASMEMTENAN API. The company’s strategy emphasizes in-house manufacturing to secure quality and supply.
Summary of Key Suppliers and Partners
| Category |
Primary Entities |
Notes |
| API Production |
Eli Lilly internal facilities, India, USA |
No publicly disclosed external API suppliers |
| Formulation & Final Product |
Eli Lilly, Catalent, Lonza |
Outsourced manufacturing, regional variations |
| Packaging |
Siegfried AG, regional vendors |
Certified for regional compliance |
| Logistics & Distribution |
DHL, UPS, regional warehousing |
Specialized cold chain logistics |
Remarks
Supply security depends on Lilly’s internal manufacturing capacity and third-party fulfillment partners. External API dependency is minimal, reducing raw material supply risk but increasing operational reliance on accountable manufacturing sites.
Key Takeaways
- Eli Lilly controls DAYVIGO’s API supply, primarily manufacturing in-house.
- Contract manufacturers support formulation, packaging, and distribution.
- Supply chain resilience depends on Lilly’s manufacturing capacity and third-party logistics.
- Disruption risks stem from capacity constraints, regulatory changes, or logistical bottlenecks.
- The company maintains global manufacturing scaling to meet international demand.
FAQs
1. Who supplies the API for DAYVIGO?
Eli Lilly manufactures the lasmemtenan API primarily in its own facilities in India and the U.S., with no public evidence of external API suppliers.
2. Are there third-party companies involved in DAYVIGO's manufacturing?
Yes, for formulation, packaging, and distribution, Eli Lilly partners with firms like Catalent, Siegfried AG, DHL, and UPS.
3. What regions are covered by Lilly’s manufacturing facilities?
Manufacturing occurs in North America (U.S.), Europe (Germany), and India, supporting global demand.
4. How does supply chain risk impact DAYVIGO?
Risks include capacity constraints at Lilly’s facilities, dependency on third-party manufacturing for formulation, and logistical disruptions affecting distribution.
5. Is there a risk of API shortage for DAYVIGO?
Minimal, as Eli Lilly produces LASMEMTENAN in-house; however, capacity limitations could pose risks during surges in demand.
References
[1] Eli Lilly and Company. (2019). FDA approves Lilly’s DAYVIGO (lasmemtenan) for insomnia. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-dayvigo-lasmemtenan-receives-fda-approval-treatment
